BioCardia, Inc. Warrant
BCDAW
BCDAW was delisted on the 2nd of August, 2024.
3 hedge funds and large institutions have $901K invested in BioCardia, Inc. Warrant in 2021 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 1 reducing their positions, and 0 closing their positions.
11% more capital invested
Capital invested by funds: $815K → $901K (+$86K)
0% more funds holding
Funds holding: 3 → 3 (0)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$381 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
1
CAPTRUST Financial Advisors
Raleigh,
North Carolina
| $812K | – | – | – |
|
2
Osaic Holdings
Scottsdale,
Arizona
| $87K | – | – | – |
|
|
3
UBS Group
Zurich,
Switzerland
| $2K | -$381 | -237 | -18% |
|
BCDAW Hedge Fund Activity: Q3 2021 in Review
3 of the 5,713 institutional investors tracked by Wall St. Rank reported a position in BioCardia, Inc. Warrant (BCDAW) for Q3 2021, worth a combined $901K — up 11% from $815K a quarter earlier.
Fund positioning in BCDAW was balanced in Q3 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was UBS Group, cutting an estimated $381.
- 3 institutional investors held BioCardia, Inc. Warrant (BCDAW) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $901K of BioCardia, Inc. Warrant stock for Q3 2021, up 11% quarter-over-quarter.
- 0 funds opened new BioCardia, Inc. Warrant positions in Q3 2021 and 0 closed out.
- The largest BioCardia, Inc. Warrant seller in Q3 2021 was UBS Group, an estimated $381 sold.
Based on aggregated 13F filings for Q3 2021.